Revance Therapeutics
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Revance Therapeutics sits in the top decile of US sponsors by registered trial count (#583 of 15,742 sponsors by registered trial count).
Revance Therapeutics: 27 sponsored US clinical trials, none currently recruiting.
Revance Therapeutics sponsors 27 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 25 completed. 8 of these trials are in Phase 3-4 (later-stage) and 19 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Facial Wrinkles, with 3 trials.
Top-decile sponsor footprint
Revance Therapeutics ranks in the top decile of sponsors by registered trial count (#583 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
25 of 27 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (92.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
27 total, page 1 of 1
Phase 2a Study of DaxibotulinumtoxinA-lanm for Injection in Dynamic Forehead Lines and Glabellar Lines
NCT06411002
Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Upper Facial Lines
NCT04259086
Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines
NCT03911102
Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Forehead Lines (Frontalis)
NCT03786770
DaxibotulinumtoxinA for Injection for the Treatment of Plantar Fasciitis
NCT03825315
Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Adult Upper Limb Spasticity
NCT03821402
Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-OLS)
NCT03617367
Single Treatment of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-1)
NCT03608397
Phase 2 DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis
NCT03137407
Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines
NCT03004248
Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines
NCT03014622
Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines
NCT03014635
DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis
NCT02973269
Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Primary Axillary Hyperhidrosis
NCT02565732
Dose-escalating Safety and Preliminary Efficacy of DaxibotulinumtoxinA for Injection in Cervical Dystonia
NCT02706795
Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Lateral Canthal Lines
NCT02580370
Efficacy and Safety of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines
NCT01940991
Open Label Study to Assess Long-term Safety of Repeat Administration of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines
NCT01818076
Efficacy and Safety Study of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines
NCT01776606
Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults
NCT01124565
A 4-Arm Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults
NCT01124552
Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults
NCT01064518
Efficacy and Safety Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
NCT00968942
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
NCT00968825
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
NCT00907387
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
NCT00884234
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
NCT00888914
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 19 |
| Phase 3 | 8 |
How the Revance Therapeutics early-phase archive is shaped
27 indexed studies, none listed as recruiting (0% open); 25 completed (93%).
Phase mix: 8 late (III/IV) vs 19 early (I/II) (early-phase heavy).
Top condition: Facial Wrinkles (3 trials), 7 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Revance Therapeutics: archived-pipeline peers nationwide
Peers matched on 27 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Revance Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 27 archived trials
- Akron Children's Hospital · 27 trials · 7% recruiting
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · 27 trials · 0% recruiting
- AVEO Pharmaceuticals · 27 trials · 7% recruiting
- Dompé Farmaceutici S.p.A · 27 trials · 15% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Revance Therapeutics page
27 registered trials is a research-attention snapshot, not an endorsement of Revance Therapeutics or any single study.
- None of Revance Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Facial Wrinkles is the condition Revance Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Facial Wrinkles trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Revance Therapeutics pipeline card: 27 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.